The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: Retrospective study of the variability in response to oral anticoagulant therapy

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 6, 2010, Pages 558-563

  Kovac, Mirjana K ^a   Maslac, Aleksandar R ^a   Rakicevic, Ljiljana B ^b   Radojkovic, Dragica P ^b  

^a Blood Transfusion Institute of Serbia   (Serbia)

^b INSTITUTE OF MOLECULAR GENETICS AND GENETIC ENGINEERING   (Serbia)

Author keywords

acenocoumarol dose; c. 1639 G>A polymorphism; variability in response to VKA; VKORC1

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K;

ADULT; AGED; ALLELE; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SERBIA; VITAMIN K; YOUNG ADULT;

EID: 77955925926     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833c2988     Document Type: Article

References (17)

1. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324:1865-1875.
2. Baglin TP, Keeling DM, Watson HG, British Committee for Standards. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006; 132:277-285.
3. Dentali F, Ageno W, Crowter M. Treatment of coumarin-associated coagulopathy: a systemic review and proposed treatment algorithms. J Thromb Haemost 2006; 4:1853-1863.
4. Wittkovsky AK. Drug interactions with oral anticoagulants. In: Colman RW, Clowes AW, Goldhaber SZ, Marder VJ, George JN, editors. Hemostasis and thrombosis, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 1699-1709.
5. Oldenburg J, Watzka M, Rost S, Muller R. VKORC1: molecular target of coumarins. J Thromb Haemost 2007; 5 (suppl1):1-6.
6. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocumarol sensitivity. Blood 2005; 106:135-140.
7. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter-individual and interethnical variability of oral anticoagulation. Thromb Haemost 2005; 94:773-779.
8. Schwarz UI, Ritchie MD, Bredford Y, Li C, Dudec S, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999-1008.
9. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784-792.
10. Montes R, Ruiz de Gaona E, Martinez-Gonzales MA, Alberca I, Hermida J. The c.-1639G>A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. B J Haematol 2006; 133:183-187.
11. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105:645-649.
12. Osman A, Enstrom C, Arbring K, Soderkvist P, Lindhal TL. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: retrospective analysis of case records. J Thromb Haemost 2006; 4:1723-1729.
13. Qazim B, Stollberger C, Krugluger W, Dossenbach-Glaninger A, Finsterer J. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Thrombolysis 2008; 28:211-214.
14. Sconce E, Kahn T, Wynne H, Avery P, Monkhouse L, King B, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: proposal for a new dosing regimen. Blood 2005; 106:2329-2333.
15. Quteinech L, Verstuyft C, Descot C, Dubert L, Robert A, Jaillon P, et al. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb Haemost 2005; 94:690-691.
16. Levine MN, Beyth R, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment. Chest 2004; 126:287S-310S.
17. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenestra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100:220-239.